Koen Demytennaere reports no conflict of interest directly related to the submitted manuscript. He is a board member and has received grants and served as a speaker in capacities unrelated to the manuscript.
EXTENDED RELEASE QUETIAPINE FUMARATE IN MAJOR DEPRESSIVE DISORDER: ANALYSIS IN PATIENTS WITH ANXIOUS DEPRESSION
Article first published online: 2 JUL 2012
© 2012 Wiley Periodicals, Inc.
Depression and Anxiety
Volume 29, Issue 7, pages 574–586, July 2012
How to Cite
Thase, M. E., Demyttenaere, K., Earley, W. R., Gustafsson, U., Udd, M. and Eriksson, H. (2012), EXTENDED RELEASE QUETIAPINE FUMARATE IN MAJOR DEPRESSIVE DISORDER: ANALYSIS IN PATIENTS WITH ANXIOUS DEPRESSION. Depress. Anxiety, 29: 574–586. doi: 10.1002/da.21970
These studies were registered at ClinicalTrials.gov (D1448C00001 study identifier number NCT00320268; D1448C00002 study identifier number NCT00321490).
- Issue published online: 3 JUL 2012
- Article first published online: 2 JUL 2012
- Manuscript Accepted: 12 MAY 2012
- Manuscript Revised: 26 APR 2012
- Manuscript Received: 13 SEP 2011
- AstraZeneca Pharmaceuticals. Grant Numbers: D1448C00001, D1448C00002
- antianxiety agents;
- antidepressive agents;
- clinical trials;
- atypical antipsychotic;
- mood disorders;
A pooled analysis was performed on data from two studies evaluating the efficacy of once-daily extended-release quetiapine fumarate (quetiapine XR) monotherapy for patients with major depressive disorder. Through these analyses (based on Hamilton Rating Scale for Depression (HAM-D) and Hamilton Rating Scale for Anxiety (HAM-A) measures), we aim to further evaluate the efficacy of quetiapine XR in depressed patients with high levels of anxiety symptoms.
Secondary analyses were conducted of pooled individual patient data from two 8-week (6-week randomized phase, 2-week drug discontinuation phase), double-blind, placebo-controlled studies of quetiapine XR (50–300 mg/day). Outcomes included change from randomization at Week 6 in Montgomery Åsberg Depression Rating Scale (MADRS) total score for patients with anxious and nonanxious depression.
Of 968 patients included in the analysis, 788 (81.4%) were classified as anxious depressed (defined as HAM-D anxiety/somatization factor score ≥7) and 180 (18.6%) were nonanxious. For patients with anxious depression and nonanxious depression, statistically significant differences versus placebo in MADRS total score were recorded for quetiapine XR 150 mg/day (−3.24, P < .001 and −4.82, P < .01, respectively) and 300 mg/day (−3.57, P < .001 and −3.39, P < .05, respectively) at Week 6. In the second analysis using an alternate definition of anxious depression (baseline HAM-A total score ≥20), quetiapine XR 150 and 300 mg/day resulted in significant differences versus placebo in MADRS total score reduction in patients with high and lower levels of anxiety. The adverse event (AE) profile was similar irrespective of baseline anxiety levels, although patients with anxious depression reported a somewhat greater incidence of AEs.
Quetiapine XR monotherapy improved symptoms of depression in patients with higher and lower levels of anxiety.